Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 01 August 2006
LentiVector licensing agreement with
Merck
Oxford BioMedica has signed a licence agreement for its LentiVector technology with Merck
The agreement allows Merck to use the company's proprietary LentiVector gene delivery system for research activities Under the terms of the agreement, Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
The patents include broad composition of matter and methods of production claims for lentiviral vector gene delivery systems of both human and non-human origin.
The LentiVector system is a powerful technology for gene delivery to a wide range of cell and tissue types.
The technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models.
It has also been shown to substantially enhance the efficiency of making transgenic birds and mammals.
Commenting on the news Oxford BioMedica's chief executive, Alan Kingsman said "This agreement with Merck is further endorsement of Oxford BioMedica's patent position in the field of lentiviral delivery systems and the broad utility of the LentiVector technology.
"We are delighted to have reached this agreement with Merck".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
